Kolltan Pharma Adds $5 Million
Kolltan Pharmaceuticals Inc., a New Haven, Conn.-based developer of oncology therapeutics, has raised $5 million in new Series A funding. The round total is now $40 million. Backers include Purdue Pharma, HBM BioCapital and the Pritzker/Vlock family.
18 August 2009•2 mins read
